Janux Therapeutics and Bristol Myers Squibb (BMS) will develop a novel, tumor-activated therapeutic in an exclusive worldwide licensing agreement. Though as yet undisclosed, the therapeutic is targeting a validated solid tumor antigen expressed across several human cancer types. As a clinical-stage biopharmaceutical company, Janux possesses a pipeline of novel immunotherapies developed via the company’s proprietary technologies. Among these are its Tumor Activated T Cell Engager, Tumor Activa...